PAOG adds synthetic bioidentical CBD to its research pipeline



Sandusky, OH, November 08, 2021 (GLOBE NEWSWIRE) – PAO Group, Inc. (OTC Pink: PAOG) today announced that the company is adding bioidentical synthetic CBD to its global research initiative.

PAOG leadership points out that CBD extracted from hemp, as the legalization of hemp continues to evolve, has certainly highlighted the multitude of potential health benefits of CBD. PAOG has a number of CBD pharmaceutical and nutraceutical developments underway. From now on, PAOG will add bioidentical synthetic CBD to its pharmaceutical and nutraceutical initiatives.

Many common over-the-counter supplements, such as vitamins C and D, are not organic compounds but are otherwise produced synthetically in the lab. Even though they are not derived from natural resources such as fruits, they are nonetheless bio-identical to natural compounds. Synthetic CBD can be produced in the same way and synthetic CBD has the potential to be more pure in terms of less contaminants from the extraction process and less presence of other conflicting cannabinoids, besides being more coherent in the structure (see “Natural or synthetic CBD“to learn more)

PAOG continues to add several new pharmaceutical products to its development pipeline in addition to its continued development of its RespRx Pharmaceutical CBD for the treatment of chronic obstructive pulmonary disease (COPD).

The company has conducted an in-depth review of its current pharmaceutical development project RespRx CBD with its partner CRO, industry consultants and other pharmaceutical companies with the aim of exploring various opportunities to accelerate and diversify development.

As part of the in-depth review, PAOG recently announced a partnership opportunity that could accelerate the ongoing development of its RespRx CBD.

As the in-depth review continues, PAOG has now identified opportunities derived from its research to initiate further pharmaceutical development projects. The identified opportunities that PAOG plans to pursue have accelerated potential and are likely to result in a pharmaceutical product reaching the market before RespRx.

Learn more about PAOG at

Forward-Looking Statements: Certain statements contained in this press release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to to the safe harbor created by these rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding the future plans and potential objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the rapid implementation of any strategically important plan described above. The Company assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact us:
Jim DiPrima


Leave A Reply

Your email address will not be published.